Wall Street Zen Downgrades Avantor (NYSE:AVTR) to Hold

Avantor (NYSE:AVTR) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other research firms have also recently weighed in on AVTR. Evercore set a $10.50 price objective on shares of Avantor in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $13.00 price target on shares of Avantor in a research note on Thursday, July 30th. Citigroup increased their price objective on shares of Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Sanford C. Bernstein initiated coverage on Avantor in a research note on Friday, June 26th. They set a “market perform” rating and a $10.50 target price on the stock. Finally, Jefferies Financial Group upgraded Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price target on the stock in a report on Wednesday, July 29th. Two investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Avantor presently has a consensus rating of “Hold” and an average target price of $12.47.

Avantor Trading Up 0.0%

AVTR opened at $15.35 on Friday. The stock has a 50-day moving average of $14.44 and a 200 day moving average of $10.86. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. Avantor has a 12 month low of $7.26 and a 12 month high of $16.05. The firm has a market cap of $10.38 billion, a P/E ratio of -18.27, a P/E/G ratio of 11.58 and a beta of 0.94.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The business had revenue of $1.69 billion for the quarter, compared to the consensus estimate of $1.61 billion. During the same period in the prior year, the business posted $0.24 earnings per share. The company’s quarterly revenue was up .5% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, research analysts forecast that Avantor will post 0.81 EPS for the current year.

Hedge Funds Weigh In On Avantor

Several institutional investors have recently made changes to their positions in AVTR. Parallel Advisors LLC lifted its position in shares of Avantor by 21.4% during the first quarter. Parallel Advisors LLC now owns 8,452 shares of the company’s stock valued at $66,000 after buying an additional 1,491 shares during the last quarter. Kera Capital Partners Inc. grew its position in shares of Avantor by 8.6% in the 4th quarter. Kera Capital Partners Inc. now owns 24,992 shares of the company’s stock worth $273,000 after buying an additional 1,971 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Avantor by 2.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 106,835 shares of the company’s stock worth $838,000 after acquiring an additional 2,274 shares in the last quarter. Hsbc Holdings PLC raised its stake in shares of Avantor by 8.0% during the 2nd quarter. Hsbc Holdings PLC now owns 33,534 shares of the company’s stock worth $332,000 after acquiring an additional 2,497 shares in the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Avantor by 3.4% during the 2nd quarter. HighTower Advisors LLC now owns 85,072 shares of the company’s stock worth $842,000 after acquiring an additional 2,787 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.